Walk into any men’s health clinic and you’ll find a striking pattern: two men with nearly identical testosterone levels on their lab report can have completely different experiences. One feels energetic, mentally sharp, and physically capable. The other reports low energy, reduced motivation, brain fog, declining muscle mass, and diminished libido — symptoms that, on paper, his testosterone level doesn’t explain. His doctor reviews the results, notes they’re within normal range, and sometimes concludes there isn’t a hormonal problem.
The problem with that conclusion is that a single total testosterone number tells only part of the story. How much of that testosterone is biologically active versus bound and unavailable, how efficiently it is converted to its more potent derivative DHT, how much of it is being converted to estrogen, how well the body clears cortisol that competes with testosterone production, and how sensitively the target tissues respond to the testosterone that does reach them — all of these variables are shaped by genetics and none of them appear on a standard testosterone panel.
Understanding the male hormone pathway from a genetic perspective doesn’t replace clinical evaluation of testosterone levels. But it adds a layer of biological context that explains why hormonal experience varies so much between men with comparable blood values, and why optimizing male hormonal health requires looking at the entire pathway rather than a single number on a test.
Contents
How Testosterone Is Made — and the Genetic Variables That Govern Production
Testosterone synthesis follows the same steroid hormone pathway as female sex hormones — beginning with cholesterol and proceeding through a series of enzymatic conversions. The key difference is in which enzymes are most active and which hormones the pathway is optimized to produce. In men, the Leydig cells of the testes are the primary site of testosterone production, under stimulation from luteinizing hormone (LH) released by the pituitary.
CYP17A1 and HSD3B1: The Synthesis Enzymes
CYP17A1 encodes an enzyme that performs two key steps in steroid hormone synthesis — converting pregnenolone to DHEA and progesterone to androstenedione. Both conversions are necessary to produce the androgen precursors that become testosterone. Variants in CYP17A1 affect the efficiency of these conversions and influence both baseline testosterone levels and the ratio of different androgen precursors in circulation.
HSD3B1 encodes 3-beta-hydroxysteroid dehydrogenase, which converts DHEA into androstenedione — another step in the androgen synthesis chain. Variants in HSD3B1 that affect enzyme activity influence how efficiently DHEA, the most abundant circulating androgen precursor, is converted toward active androgens including testosterone. DHEA and DHEA-S levels decline substantially with age, making the efficiency of their conversion to downstream androgens increasingly important as men get older.
SHBG: The Variable That Makes Total Testosterone Misleading
Sex hormone-binding globulin binds testosterone — and DHT, and estradiol — rendering them biologically inactive. Only free, unbound testosterone can enter cells, bind androgen receptors, and exert effects on target tissues. A man’s total testosterone level is the sum of bound and free testosterone combined, but it is only the free fraction that matters biologically.
Variants in the SHBG gene determine how much of this binding protein circulates. High SHBG genetics produces more binding protein, which sequesters more testosterone and reduces the free fraction. A man with high SHBG genetics and a testosterone level of 550 ng/dL may have less biologically active testosterone than a man with low SHBG genetics and a total testosterone of 400 ng/dL, because the second man has a higher proportion circulating in the free form. This is one of the most important genetic variables in male hormonal health and one of the least routinely evaluated in standard care.
Testosterone Conversion: DHT, Estrogen, and What Happens After Production
Once produced, testosterone doesn’t simply stay as testosterone. A portion is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase, and another portion is converted to estradiol by aromatase. The balance between these conversions is critical for male hormonal health, and both processes are genetically variable.
DHT, the Androgen Receptor, and Why Some Men Are More Sensitive to Androgens
DHT is roughly three to five times more potent than testosterone as an androgen receptor activator. It binds the androgen receptor (AR) with higher affinity and produces stronger androgenic effects in target tissues. DHT is the primary androgen responsible for prostate growth, and it plays central roles in libido, body hair distribution, and the hair follicle miniaturization that produces male pattern baldness.
The AR gene contains a polymorphic CAG repeat region — a stretch of repetitive DNA that varies in length between individuals. Shorter CAG repeat lengths produce a more sensitive androgen receptor that generates stronger responses to both testosterone and DHT. Longer repeats produce a less sensitive receptor. This is why two men with identical DHT levels can have very different androgenic outcomes: the man with shorter CAG repeats has tissue-level androgen sensitivity amplified by receptor genetics. This variant has implications for everything from muscle-building response to exercise, to libido, to prostate cancer risk — where receptor sensitivity modulates how prostate tissue responds to androgenic stimulation.
CYP19A1 and Estrogen in Men: The Balance That Most Men Overlook
Aromatase, encoded by CYP19A1, converts testosterone to estradiol. Estrogen in men is not merely a byproduct to be suppressed — it plays important roles in bone density maintenance, cardiovascular health, cognitive function, and libido. The problem arises when aromatase activity is excessive, converting too large a proportion of available testosterone to estrogen and producing symptoms of estrogen excess alongside low testosterone: gynecomastia, water retention, reduced libido, mood changes, and a shift in body composition toward greater fat storage.
Visceral fat tissue expresses high levels of aromatase, which is why excess body fat accelerates testosterone-to-estrogen conversion — creating a cycle where lower testosterone promotes fat gain, and increased fat tissue further converts remaining testosterone to estrogen. CYP19A1 variants that produce higher baseline aromatase activity make men more susceptible to this pattern. Combined with CYP1B1 variants that produce more reactive estrogen metabolites during Phase I metabolism, high-aromatase genetics can create hormonal dynamics that significantly affect body composition and wellbeing even when total testosterone is technically normal.
Cortisol, Stress, and the Testosterone-Suppressing Effect of HSD11B1
Testosterone and cortisol are biological antagonists in several important ways. Cortisol suppresses the hypothalamic-pituitary-testicular (HPT) axis — the signaling cascade that drives testosterone production — at multiple levels. Acutely, the cortisol released during intense exercise or psychological stress suppresses LH secretion, reducing the testicular stimulus for testosterone synthesis. Chronically elevated cortisol competes for the same precursor pathways as testosterone, diverting pregnenolone toward cortisol at the expense of androgen production.
The HSD11B1 gene encodes an enzyme that activates cortisol from its inactive precursor cortisone in peripheral tissues including fat, liver, and muscle. Variants in HSD11B1 that increase its activity produce more local cortisol activation in tissues — contributing to the metabolic effects of cortisol, including insulin resistance, visceral fat accumulation, and suppression of testosterone production, even when circulating cortisol measured in a morning blood draw appears normal. Men with high-activity HSD11B1 variants may be experiencing a larger cortisol-driven suppression of testosterone than their total cortisol level suggests.
This genetic variable is particularly relevant for men who notice that testosterone-related symptoms worsen significantly during stressful periods, or who find that stress management interventions produce more improvement in energy and vitality than expected. The HSD11B1 connection explains why managing psychological and physiological stress is not just a mental health recommendation for male hormonal optimization — it is a direct input into the testosterone production axis.
Estrogen Clearance in Men: COMT, MTHFR, and Why Methylation Matters
Just as in women, the estrogen that men produce from testosterone aromatization must be metabolized and cleared. The same Phase I and Phase II pathways operate in men: CYP1A1 and CYP1B1 determine which estrogen metabolites are produced, and COMT methylates catechol estrogen metabolites for excretion. Men with slow-activity COMT variants and impaired MTHFR-driven methylation capacity accumulate estrogen metabolites more readily, potentially amplifying the estrogenic effects of whatever testosterone-to-estrogen conversion their aromatase genetics is producing.
This COMT-MTHFR-CYP1B1 interaction in estrogen clearance is as relevant in men as it is in women, and it is rarely discussed in the context of male hormonal health. For men with symptoms suggestive of estrogen excess — despite total estrogen levels appearing only modestly elevated — poor estrogen clearance genetics may be a significant contributing factor. Supporting methylation through adequate folate, B12, and B6 status, and ensuring liver Phase II detoxification is functioning optimally, directly supports estrogen clearance in genetically predisposed men.
Curious about how your own genes influence testosterone production, DHT conversion, androgen receptor sensitivity, aromatase activity, cortisol interaction, and estrogen clearance? SelfDecode offers a personalized Male Hormones Pathway DNA report that maps your entire male hormone biochemistry through visual pathway diagrams and provides science-backed recommendations tailored to your specific genetic profile.
Male hormonal health is more than a testosterone number. It is a pathway — from cholesterol to pregnenolone to DHEA to androstenedione to testosterone, then branching to DHT and estradiol, clearing through methylation and Phase I and II detoxification — and every step in that pathway is genetically variable. The man who feels hormonally suboptimal despite a “normal” testosterone level is not imagining things. His experience may reflect bottlenecks or imbalances elsewhere in the pathway that a single blood value doesn’t capture.
Understanding the genetic architecture of your own male hormone pathway gives you a more complete picture than any standard panel can provide. It identifies where your system is likely efficient and where it may be hitting constraints, and it points toward the interventions — dietary, supplemental, lifestyle-based — most likely to improve hormonal balance given your specific genetic starting point rather than the average man’s.